which when administered in adequate amounts confer a health benefit on the host" (Joint FAO/WHO Working Group, 2002) . The studies that evaluated the effects of probiotics on the treatment of periodontal disease demonstrated that they can reduce periodontopathogens, improve periodontal clinical parameters, decrease the levels of proinflammatory cytokines, and potentiate the effects of SRP Shah, Gujjari, & Chandrasekhar, 2013; Tekce et al., 2015; Teughels et al., 2013; Vivekananda, Vandana, & Bhat, 2010) . In fact, two meta-analyses seem to support the adjunctive use of probiotics in the treatment of chronic periodontitis (Ikram, Hassan, Raffat, Mirza, & Akram, 2018; Martin-Cabezas, Davideau, Tenenbaum, & Huck, 2016) . Nevertheless, further high-quality randomized clinical trials with microbiological outcomes are warranted to obtain strong conclusions in this regard (Ikram et al., 2018) .
To date, studies on the effects of probiotics on periodontal diseases have used mainly microorganisms of the genus Lactobacillus.
However, other potential probiotics should be investigated. Hojo et al. (2007) observed that Bifidobacterium species and their counts could be associated with periodontal health and with treatment success in patients with periodontitis. In an in vitro study, Jasberg, Soderling, Endo, Beighton, and Haukioja (2016) demonstrated that species of the genus Bifidobacterium can adhere strongly to the subgingival biofilm and significantly reduce the count of Porphyromonas gingivalis.
Only two pre-clinical studies evaluated the effect of bacteria of the genus Bifidobacterium on periodontal disease Ricoldi et al., 2017) . Oliveira et al. (2017) demonstrated that the topical use of Bifidobacterium animalis subsp. lactis HN019 promotes a protective effect against alveolar bone loss and connective tissue attachment loss attributable to experimental periodontitis in rats. Ricoldi et al. (2017) concluded that the oral administration of B. lactis HN019 potentiates the effects of SRP on experimental periodontitis in rats. Considering the clinical use of Bifidobacterium on periodontal diseases, there is only one clinical trial that investigated the effects of 4-week use of yogurt supplemented with Bifidobacterium animalis subsp. lactis DN-173010 versus a placebo yogurt, followed by a 5-day non-brushing period, on gingivitis (Kuru, Laleman, Yalnizoglu, Kuru, & Teughels, 2017) . The authors concluded that the probiotic can have a positive effect on plaque accumulation and gingival inflammatory parameters after oral hygiene abstinence.
So far, no clinical study has investigated the effects of bacteria of the genus Bifidobacterium on non-surgical treatment of periodontitis. This randomized placebo-controlled clinical trial evaluated the effects of B. lactis HN019-containing probiotic lozenges as adjuvant to SRP in patients with generalized chronic periodontitis. The sample size was determined using Graphpad Statemate 2.0 (GraphPad Software, Inc., San Diego, CA, USA). An 80% power was adopted to recognize a significant difference of 1 mm (d) between groups with a 95% confidence interval (α = 0.05) and standard deviation (SD) of 1.13 mm (Vivekananda et al., 2010) .
| MATERIAL S AND ME THODS

| Patient population
Considering changes in mean clinical attachment level (CAL) as the primary outcome variable and (Zα + Zß) 2 = 7.84 (Zα = 1.96 for 2-tailed 0.05 hypothesis test; Zß = 0.842 for power = 0.8), sample size was calculated using the following formula:
]} × (Zα + Zß) 2 . Therefore, a total of 36 patients were required.
However, considering that some patients could be lost to follow-up, 41 patients were enrolled in this study.
| Inclusion and exclusion criteria
All patients were diagnosed with generalized chronic periodontitis according to the classification of the American Academy of Periodontology (Armitage, 1999) . The inclusion criteria were (a) age over 30 years, (b) 30% or more of the sites with probing pocket depth (PPD) ≥ 4 mm and CAL ≥ 4 mm, (c) presence of bleeding on probing (BOP) and (d) a minimum of five teeth with at least one site with CAL and PPD ≥ 5 mm. All patients had to be in good general health.
The exclusion criteria were (a) cause-related periodontal therapy or antimicrobial therapy in the previous 6 months, (b) dental procedures, (e) long-term administration of anti-inflammatory medications, and (f) usage of probiotics 6 months prior to the study.
| Experimental design, allocation concealment, and treatment protocol
According to a random numeric were not subjected to any clinical procedure during these visits.
One research assistant (P.H.F.S.) conducted these procedures and monitored the patient's compliance with medication dosage. This assistant was not the examiner or operator in this study.
All patients received microbiological, immunological, and clinical monitoring at baseline, at 30 days, and at 90 days. The evaluations (pre-and post-intervention) were conducted by a single trained and calibrated examiner (M.S.M.S.), who was blinded to the experimental groups.
| Examiner calibration
The Kappa coefficient greater than or equal to 0.85 was used for examiner calibration. Ten patients with at least five teeth with PPD and CAL ≥ 5 mm on proximal sites were selected. Each patient was examined twice by a universal North Carolina-15 periodontal probe (PCPUNC156; Hu-Friedy), at a 48-hour interval between the first and second assessments.
| Clinical measurements
Plaque index (PI) was employed to assess the patients' oral hygiene status. BOP was recorded based on the presence or absence of bleeding up to 20 s after probing at the experimental sites. PI and BOP were scored as plaque and bleeding being absent or present (0 or 1, respectively). PPD was measured from the free gingival margin to the bottom of the periodontal pocket. CAL was measured from the cementoenamel junction to the base of the periodontal pocket. Gingival recession (GR) was measured from the cementoenamel junction to the free gingival margin. BOP, PPD, CAL, and GR were measured at six sites per tooth. All probing measurements were performed using a manual periodontal probe (PCPUNC156;
Hu-Friedy).
| Immunological monitoring
Gingival crevicular fluid (GCF) was collected from four noncontiguous interproximal sites per patient using absorbent paper strips (Periopaper ® ; Oralflow Inc., Amityville, NY, USA), as previously described by Luchesi et al. (2013) . Conventional enzyme immunoassays (ELISA) using commercially available kits (DCTM Protein Assay; Bio-Rad Laboratories, Inc. Berkeley, CA, USA)
were performed to determine the amount of total protein in each sample. IL-1β, IL-10, and IL-8 levels in GCF samples were determined according to Moreira et al. (2015) using high sensitivity kits (LXSAHM-03-Techne Corporation, R&D Systems, Minneapolis, MN, USA) and the multiplexing instrument (MAGPIX ® analyser;
Luminex Corporation, Austin, TX, USA). These cytokines were selected considering the study by Ricoldi et al. (2017) , which demonstrated the effects of B. lactis HN019 on these immunoinflammatory markers in periodontal tissues of rats. The concentrations of each cytokine were estimated from the standard curve using a five-parameter polynomial equation with specific software (Xponent ® software; Luminex Corporation).
| Microbiological monitoring
According to Moreira et al. (2015) , subgingival plaque samples were obtained from four non-contiguous interproximal sites from each patient, grouped according to the following PPD categories: moderate pockets (PPD = 4-6 mm) and deep pockets (PPD ≥ 7 mm). The samples were individually analysed for the presence of 40 subgingival bacterial species using the checkerboard DNA-DNA hybridization technique (Socransky et al., 2004) at the Microbiology Laboratory of the Guarulhos University (UNG, Guarulhos, SP, Brazil).
Bifidobacterium animalis subsp. lactis HN019 was detected and quantified by real-time polymerase chain reaction (qPCR) using specific primers, as proposed by Junick and Blaut (2012) . Genomic DNA was extracted, and the qPCR technique was performed using the SYBRGreen system (Invitrogen Corp., Carlsbad, CA, USA) in StepOne Plus ™ Real-Time (Thermo Fisher Scientific).
| Outcome variables
Changes in the mean CAL at 90 days post-SRP were defined as the primary outcome variable. All other parameters were considered secondary outcomes. Sub-analyses were made considering PPD at baseline for clinical (PPD, CAL, and GR) and microbiological parameters. Periodontal pockets were classified at baseline as moderate (PPD = 4-6 mm) or deep (PPD ≥ 7 mm).
The "need for additional periodontal treatment" was determined according to Cionca, Giannopoulou, Ugolotti, and Mombelli (2009) .
"Risk for periodontal disease progression" was defined at the patient level according to Lang and Tonetti (2003) .
F I G U R E 1 Flowchart of the study design
| Statistical analysis
Each outcome was computed per participant and then averaged across patients in both groups. The significance level was set at 5%.
Within-group and between-group differences in PPD, CAL, GR, PI, BOP, and residual periodontal pockets were assessed by repeated measures analysis of variance (ANOVA) followed by Bonferroni post hoc test and by Student's t test, respectively. The differences between groups considering the outcomes "need for additional periodontal treatment" and "risk for periodontal disease progression" were assessed by the chi-square test.
Microbiological data were presented as mean counts (x10 5 ) of individual bacterial species in both groups. Bacterial species were also grouped into complexes, according to Socransky, Haffajee, Cugini, Smith, and Kent (1998) . Friedman's test was used to detect significant differences within each group. The analyses were performed after adjustments for multiple comparisons (Socransky, Haffajee, Smith, & Dibart, 1991) The between-group differences in the changes observed at 90 days regarding the mean counts of each bacterial species compared to baseline values were assessed by the Mann-Whitney test. The within-group and between-group differences in the number of copies of B. lactis HN019 DNA were also assessed by the MannWhitney test.
Total protein values were converted to pg/mL. Final cytokine levels were obtained by dividing the initial values provided by the MAGPIX ® system by the total protein content in GCF samples (pg/mL). Withingroup and between-group differences in the mean levels of IL-1β, IL-8, and IL-10 were assessed by ANOVA followed by Bonferroni post hoc test and Student's t test, respectively.
| RE SULTS
This study started in December 2015 and ended in August 2016. As to the risk of progression of periodontal disease (Table 2) , while 55% of the patients in the Test group were at a low risk, only 30% of the patients in the Control group were classified as such. The
| Clinical monitoring
Test group had a lower rate of patients in need for additional periodontal treatment on more than three sites when compared to the Control group at 90 days (p < 0.05). Figure 2 shows the mean total count (×10 
| Microbiological monitoring
| Immunological monitoring
IL-8, IL-1β, and IL-10 levels are shown in Figure 5 (a-c). Only the Test group had higher levels of IL-10 than those at baseline at 30 days (p < 0.05). 
| D ISCUSS I ON
TA B L E 1 (Continued)
In the present study, whereas 58% of pockets diagnosed at baseline with PPD ≥ 7 mm decreased to PPD ≤ 3 mm at 90 days in the Test group, only 22% of deep pockets in the Control group were reduced. Teughels et al. (2013) Modulation of the host's microbiota is one of the basic mechanisms that may explain the beneficial effects of probiotics on periodontal health. The Test group presented higher rates of commensal bacteria on subgingival biofilm when compared with the Control group at 90 days. These commensal bacteria are associated with periodontal health (Aas, Paster, Stokes, Olsen, & Dewhirst, 2005; Abusleme et al., 2013; Aruni, Dou, Mishra, & Fletcher, 2015; Hajishengallis, Darveau, & Curtis, 2012; Lucas, Beighton, & Roberts, 2000) , and they can help control inflammation and infection of periodontal tissues (Devine, Marsh, & Meade, 2015; Kumar & Mason, 2015) . Compared with the Control group, the Test group presented lower proportions of some Gram-negative anaerobic bacteria species involved in the pathogenesis of periodontal diseases. In a preclinical study, Oliveira et al. (2017) demonstrated that B. lactis HN019 reduces the amount of periodontopathogens on biofilm.
The possible coaggregation of Bifidobacterium with Fusobacterium nucleatum can reduce the amount of binding sites for periodontopathogens on biofilm (Haukioja et al., 2006) . Furthermore, probiotic bacteria can produce several components that act as antimicrobial agents (Gillor, Etzion, & Riley, 2008; Gordon, 2009) . Some in vitro studies have shown that Bifidobacterium can inhibit the growth of periodontopathogens such as P. gingivalis (Jasberg et al., 2016; Zhu, Xiao, Shen, & Hao, 2010) .
In the present study, whereas no differences were observed between the Control and Test groups at 30 postoperative days regarding the proportions of red complex bacteria, the Control Group had higher percentual of these bacteria at 90 days. It could suggest that probiotic might have acted delaying the recolonization of periodontal pockets by these bacteria in the Test Group. Tekce et al. (2015) observed that patients treated with SRP and probiotics presented improvements in the rates of strict anaerobic microorganisms on subgingival biofilm and that these rates became similar to those of the patients treated exclusively with SRP only at 360 postoperative days. Differently from these results with probiotics, the effects of antibiotics on delayed recolonization of periodontal pockets seem to occur in the short term. Mdala et al. (2013) and Bizzarro et al. (2016) have shown that no differences were seen in the number of red complex pathogens between patients treated with SRP and those treated with SRP combined with antibiotic therapy after 3 months. TA B L E 2 Number and percentage of subjects presenting low (≤4 sites with probing pocket depth (PPD) ≥ 5 mm), moderate (5-8 sites with PPD ≥ 5 mm) or high (≥9 sites with PPD ≥ 5 mm) risk for disease progression, as well as presenting 0, 1-2 or ≥3 sites in need for additional therapy F I G U R E 2 Profiles of the mean counts (×10 5 ) of 40 taxa in subgingival biofilm samples at baseline and at 30 and 90 days post-treatment.
The panel at the far right presents the changes in the mean counts of each species between baseline and 90 days post-treatment. The species were ordered according to the microbial complexes described by Socransky et al. (1998) . The significance of differences among time points was determined using Friedman test (*p < 0.05 at 30 days and # p < 0.05 at 90 days) and between groups at 90 days using MannWhitney test ( & p < 0.05). All the analyses were adjusted for multiple comparisons (Socransky et al., 1991) . 
| CON CLUS ION
The use of B. lactis HN019 as an adjunct to SRP offers additional clinical, microbiological, and immunological benefits in the treatment of periodontal pockets in patients with generalized chronic periodontitis.
F I G U R E 3 Cumulative mean proportions of microbial complexes in subgingival biofilm samples taken from subjects at baseline and at 30 and 90 days post-treatment. The colours represent different microbial complexes (Socransky et al., 1998) . The light green colour represents the proportion of Aa. The grey colour represents species that did not fall into any complex, and Actinomyces species are represented in blue. The significance of differences among time points was determined using Friedman and Dunn multiple-comparison tests (different letters represent significant differences between time points, p < 0.05). The significance of differences between the two groups at 30 days and 90 days was determined by using Mann-Whitney test (*p < 0.05 at 30 days and **p < 0.05 at 90 days) 
